You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Investigational Drug Information for AG-120


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug AG-120?

AG-120 is an investigational drug.

There have been 28 clinical trials for AG-120. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2019.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Cancer Institute (NCI), and Institut de Recherches Internationales Servier.

There are nineteen US patents protecting this investigational drug and two hundred and ninety-two international patents.

Recent Clinical Trials for AG-120
TitleSponsorPhase
Ivosidenib or Enasidenib Followed by Azacitidine Plus Venetoclax or Azacitidine Plus Venetoclax Followed by Ivosidenib or Enasidenib for the Treatment of IDH Mutated Acute Myeloid Leukemia in Older Patients. The I-DATA StudyAlice MimsPhase 2
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionNational Cancer Institute (NCI)Phase 1
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionM.D. Anderson Cancer CenterPhase 1

See all AG-120 clinical trials

Clinical Trial Summary for AG-120

Top disease conditions for AG-120
Top clinical trial sponsors for AG-120

See all AG-120 clinical trials

US Patents for AG-120

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-120 ⤷  Try a Trial Methods of treatment of malignancies Celgene Corporation (Summit, NJ) Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
AG-120 ⤷  Try a Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try a Trial
AG-120 ⤷  Try a Trial Methods of treatment of malignancies Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
AG-120 ⤷  Try a Trial Pharmaceutical compositions of therapeutically active compounds Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-120

Drugname Country Document Number Estimated Expiration Related US Patent
AG-120 Australia AU2016393869 2036-02-26 ⤷  Try a Trial
AG-120 Australia AU2016393870 2036-02-26 ⤷  Try a Trial
AG-120 Canada CA3015753 2036-02-26 ⤷  Try a Trial
AG-120 Canada CA3015757 2036-02-26 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.